Literature DB >> 33021061

Analysis of routine blood markers for predicting amputation/re-amputation risk in diabetic foot.

Anıl Gülcü1, Mustafa Etli2, Oğuz Karahan2, Ahmet Aslan1.   

Abstract

Diabetic foot is challenging progressive disease which requires multisystemic control. Neuropathy, arteriopathy, and cellular responses should treated collaboratively. Despite all medical advances, diabetic foot can highly resulted with amputation and also re-amputation can be required because of failed wound healing. In this study, we aimed to investigate the relation between blood parameters and amputation events. Diabetic 323 patients include to the study who referred to orthopaedic clinic for amputation. Amputation levels (amputation levels phalanx, metatarsal, lisfranc, syme, below knee, knee-disarticulation, above-knee amputation) and re-amputations recorded and compared with routine blood parameters. Re-amputation was observed at 69 patients. The significant difference detected between lower albumin, higher HbA1c, higher CRP levels (P < 0.05) in regards to gross amputation levels, and increased wound depth. Furthermore, lower albumin levels and higher levels of WBC, HbA1c, CRP, and Creatinine were detected in re-amputation levels. Especially, HbA1c, CRP, and Creatinine levels were found as upper bound of reference line for re-amputation. The statistically optimal HbA1c cutoff point for diabetes was ≥7.05%, with a sensitivity of 86% and a specificity of 59%. In according to our results, simple blood parameters can be useful for observing the progress of amputation in diabetic foot. Particularly, lower albumin, and higher HbA1c, CRP, and Creatinine levels detected as related with poor prognosis. Besides, screening of HbA1c level seems to be highly sensitive for detecting of re-amputation possibility.
© 2020 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd.

Entities:  

Keywords:  HbA1c; amputation levels; blood parameters; diabetic foot; re-amputation

Year:  2020        PMID: 33021061      PMCID: PMC7948900          DOI: 10.1111/iwj.13491

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


INTRODUCTION

Diabetes is a worldwide problem that effects to multi‐organ systems and a component of the challenging syndromes such as metabolic syndrome. Also neuronal system, renal system, arterial system (which implicates organ perfusion), retinal tissue, and wound healing are affected by hyperglycemia due to insulin. , Especially wound healing processes are affected in different steps and it leads to nonhealing ulcers which can be ended extremity loss. Some causes of nonhealing ulcerative wounds can be listed as colonisation of microorganisms, disintegration of injured epithelial barrier, disrupted immune defence, and functional abnormalities at connective and subcutaneous tissue. When combined of these underlying wound pathologies with neuropathy and impaired vascular flow, diabetic wounds are usually occurs at feet which is named as diabetic foot. , , Cellular healing mechanisms has affected in diabetic patients. Toxic potential of higher blood glucose levels against fibroblasts and mitochondrial activity has already shown. , , The increased blood glucose leads to producing of reactive oxygen species and break down oxidative balance. Antioxidant capacity is reduced and cellular senescence and apoptosis is triggered. , , , Thus, wounds are not healing regularly and that can be result with comorbidities such as diabetic foot. Nonhealed ulcers can be resulted with extremity loose, because of infection and insufficient oxygenation. , , , , Moreover, impaired wound healing leads to re‐amputations in treated segments which was amputated formerly for treatment of gangrene and infection. In previous studies, investigators focused on the possible blood predictors for determining to the re‐amputation requirement. Serum albumin, haemoglobin (Hb), white blood cell count (WBC), netrophils, neutrophil/lymphocyte ratio, C‐reactive protein (CRP) levels, and also glycated haemoglobin (HbA1c) levels as predictor of glucose metabolism were studied in previous studies. , , In according to obtained results of these previous studies, impaired blood glucose control and unregulated HbA1c was found as one of strong predictor for predicting to re‐amputation in diabetic patients. , , Thus, in this study we aimed to investigate the relationship between routinely tested blood markers and re‐amputation rates in diabetic foot patients. Additionally, we targeted to sensitivity and specificity of these markers for predicting to determining re‐amputation probability in diabetic foot patients who had previous amputation history.

MATERIAL AND METHOD

Ethical approval was obtained from human ethical committee of University. The study protocols were designed in according to Helsinki Declaration and in adherence to local guidelines for good clinical practice. After determination of all steps, the diabetic foot patients who admitted to orthopaedic clinic for extremity amputation were recorded retrospectively between 2003 and 2018. Type 2 diabetes mellitus cases, diabetic foot patients with requirement of amputation, and patients available for past medical records at least 2 years were detected as inclusion criteria. Traumatic or nondiabetic amputations, patients with nonrecorded first amputation, and patients with other systemic diseases (malignancies, immune syndromes etc.) were excluded from the study. After included to the study the demographical findings, depth of wound, duration of diabetes were recorded.

Staging

The Wagner‐Meggitt classification system was used for diabetic foot classification. Health status and comorbidity of patients were classified in according to ASA criteria. The decision of amputation and/or re‐amputation was given from the diabetic foot committee in according to following criteria: Clinical findings; gangrenous colour changes of skin, foul smell relates to anaerobic colonisation; necrosis; progressive unresponsive septic or toxic clinic in spite of medical treatment. Diagnostic markers; Irreversible ischemic changes that was supported with ankle‐brachial index evaluation (lower than 0.8) and illustrated with vascular Doppler ultrasound. After determining the appropriately perfused and noninfected area amputation levels were selected as: Digital (phalanx), Ray amputation, Trans‐metatarsal, Lisfranc, Syme's, Trans‐tibial (below knee), Knee disarticulation, and Trans‐femoral (above knee). After operation every patients was taken into orthopaedic clinics and collaboratively followed up for blood glucose and blood parameters regulation, daily wound dressing, rehabilitation, and prosthesis application if it is necessary. Completely healed skin lesions and nonrecurrence at least following 6 months were accepted as total cure.

Blood parameters

Retrospectively routine blood parameters before application of amputation were controlled. Haemoglobin (Hb) [g/dL], white blood cell count (WBC) [K/μL], Albumin [g/dL], Glycated haemoglobin (HbA1c) (%), C‐reactive protein (CRP) [mg/dL], and creatinine [mg/dL] levels were recorded.

Statistical analyse

All collected data were analysed by using SPSS software program (ver. 15.0, Chicago, Illinois). Continuous values expressed as mean ± SD and categorical values were expressed with percentages. The differences between groups were analysed with using Mann–Whitney U test. Optimal cut‐off value of significant parameters for predicting amputations/re‐amputations with expressing maximum sensitivity and specificity were detected by using receiver operator characteristic (ROC) curve analysis. Accuracy of test was detected with using area under curve (AUC) values. The statistical significance was considered in according p values smaller that 0.05.

RESULTS

Totally 323 patients were included to the study. The mean age of patients was found as 64.01 ± 12.17. Gender distribution was detected as 94 (29%) female and 229 (71%) male. The involved side was found as 147 (45.5%) left, 168 (52%) right, 8 (2.5%) bilaterally. The amputation levels were listed at Table 1 and depth of wounds presented at Table 2.
TABLE 1

Amputation levels of patients

Level n %
Phalanx4915.2
Trans‐metatarsal3811.8
Lisfranc4513.9
Syme's5617.3
Below knee8125.1
Knee disarticulation165.0
Above knee3811.8
Total323100.0
TABLE 2

Depth of wound

Depth of Wound n %
1103.1
25115.8
311535.6
410833.4
53912.1
Total323100.0
Amputation levels of patients Depth of wound The statistical difference was significant between amputation levels in regards of albumin, HbA1c, CRP, and creatinine levels (P < 0.001). Below knee and higher segment of amputation groups has lower albumin levels when compared with foot level amputation groups. Moreover, HbA1c (%) levels were detected as <7.0 in foot level amputation groups and >7.5 in below knee and higher segment of amputation groups (P < 0.001). Consecutively, CRP and creatinine levels were detected as ≤4.04 and ≤ 1.74 mg/dL in foot level amputation groups and ≥5.13 and ≥1.98 mg/dL in below knee and higher segment of amputation groups (P < 0.001). There is no significant differences between amputation levels in regards of haemoglobin and WBC levels. The distribution of amputation levels and laboratory markers listed at Table 3.
TABLE 3

Laboratory findings for each amputation segments groups

Blood ParameterAmputation Segment n Mean ± Std. Deviation95% Confidence Interval for Mean
Lower BoundUpper Bound
Albumin (g/dL)Phalanx494.314 ± 0.58424.1464.482
Trans‐metatarsal383.895 ± 0.74723.6494.140
Lisfranc453.953 ± 0.62623.7654.141
Syme's573.936 ± 0.75473.7344.138
Below knee813.389 ± 0.74753.2243.554
Knee disarticulation163.400 ± 0.67633.0403.760
Above knee373.296 ± 0.64503.0813.511
WBC (K/μL)Phalanx499576.22 ± 4880.2378174.4510 977.99
Trans‐metatarsal3811 430.79 ± 4406.6139982.3712 879.21
Lisfranc459832.22 ± 4078.0118607.0511 057.39
Syme's5710 712.50 ± 3566.0599757.5011 667.50
Below knee8110 620.42 ± 3357.6029877.9911 362.85
Knee disarticulation1610 740.00 ± 3660.8108789.2912 690.71
Above knee3710 209.74 ± 3917.4848922.0911 497.38
Hb (g/dL)Phalanx4913.047 ± 1.351612.65913.435
Trans‐metatarsal3817.195 ± 21.529110.11824.271
Lisfranc4514.200 ± 14.24599.92018.480
Syme's5712.368 ± 1.760811.89612.839
Below knee8112.662 ± 11.891810.03215.291
Knee disarticulation1611.194 ± 2.072810.08912.298
Above knee3711.415 ± 1.698110.85711.973
HbA1c (%)Phalanx496.676 ± 0.33706.5796.772
Trans‐metatarsal387.105 ± 0.59596.9097.301
Lisfranc457.044 ± 0.51016.8917.198
Syme's577.005 ± 0.56586.8547.157
Below knee817.574 ± 0.62947.4347.714
Knee disarticulation167.833 ± 0.47167.5728.094
Above knee377.665 ± 0.68267.4277.903
CRP (mg/dL)Phalanx494.2000 ± 3.876043.02165.3784
Trans‐metatarsal384.0441 ± 2.762873.08015.0081
Lisfranc453.8619 ± 3.405872.80064.9232
Syme's573.5942 ± 2.835792.80474.3837
Below knee815.1338 ± 3.870734.25526.0123
Knee disarticulation166.6733 ± 4.074924.41678.9299
Above knee376.6778 ± 4.704965.08588.2697
Creatinine (mg/dL)Phalanx491.1340 ± 0.385331.01401.2541
Trans‐metatarsal381.5252 ± 0.859771.20981.8405
Lisfranc451.5992 ± 1.522051.10582.0926
Syme's571.7430 ± 1.527961.29442.1916
Below knee811.9836 ± 1.298531.68282.2845
Knee disarticulation162.2554 ± 1.524011.33443.1763
Above knee372.5612 ± 1.760231.93713.1854
Laboratory findings for each amputation segments groups The was a significant difference between wound depth classes in regards of albumin, HbA1C, and CRP levels (P < 0.001). Increased depth of wound groups , has lower albumin levels when compared with lower depth wound (1, 2, and 3) groups. Moreover, HbA1c (%) levels were detected as <7.0 in lower depth wound groups and >7.5 in higher depth wound groups (P < 0.001). Consecutively, CRP and creatinine levels were detected as ≤4.40 and ≤1.52 mg/dL in lower depth wound groups and ≥4.91 and ≥2.22 mg/dL in in higher depth wound groups (P < 0.001). There is no significant differences between amputation levels in regards of haemoglobin and WBC levels. The distribution of wound depths and laboratory markers listed ant Table 4.
TABLE 4

Laboratory findings for each wound depth groups

Blood ParametersWound Depth n Mean ± Std. Deviation95% Confidence Interval for Mean
Lower BoundUpper Bound
Albumin (g/dL)1104.260 ± 0.62043.8164.704
2514.250 ± 0.58814.0834.417
31153.945 ± 0.69113.8184.073
41083.433 ± 0.70353.2993.568
5393.307 ± 0.83823.0353.578
WBC (K/μL)11010 054.03 ± 5876.3075850.3714 257.68
25110 031.18 ± 4102.9488877.2011 185.15
311510 271.91 ± 4076.4919518.8711 024.96
410810 902.86 ± 3858.83010 166.7711 638.95
53910 131.03 ± 3178.7289100.6011 161.45
Hb (g/dL)11013.490 ± 1.227012.61214.368
25112.878 ± 1.329612.50413.252
311512.190 ± 1.678711.88012.500
410814.046 ± 15.895411.01417.078
53914.160 ± 17.03498.63819.682
HbA1c (%)1106.670 ± 0.18296.5396.801
2516.743 ± 0.40106.6286.858
31156.982 ± 0.52626.8857.080
41087.542 ± 0.59747.4267.657
5397.839 ± 0.65497.6248.055
CRP (mg/dL)1104.3600 ± 5.19020.64728.0728
2513.8277 ± 3.333602.84894.8064
31153.9398 ± 3.221323.31024.5694
41084.9772 ± 3.722904.24235.7122
5397.0564 ± 4.422305.62298.4900
Creatinine (mg/dL)1101.0340 ± 0.386870.75721.3108
2511.2591 ± 0.481561.11271.4055
31151.5218 ± 1.394751.23611.8075
41082.2232 ± 1.493761.92062.5259
5392.2174 ± 1.406781.73422.7007
Laboratory findings for each wound depth groups There was a significant difference between American Society of Anaesthesiologists Classification (ASA) groups in regards of albumin, creatinine, HbA1C, and CRP levels (P < 0.001). Patients in higher ASA classes , has lower albumin levels when compared with lower ASA (1, 2, and 3) classes. Moreover, HbA1c (%) levels were detected as <7.24 in lower ASA classes and >7.86 in higher ASA classes (P < 0.001). Consecutively, CRP and creatinine levels were detected as ≤4.59 and ≤1.99 mg/dL in lower ASA classes and ≥4.92 and ≥2.49 mg/dL in higher ASA classes (P < 0.001). There is no significant differences between amputation levels in regards of haemoglobin and WBC levels. The distribution of ASA classes and laboratory markers listed ant Table 5.
TABLE 5

The distribution of laboratory markers in regards of American Society of Anesthesiologists Classification (ASA)

Blood ParametersASA Class n Mean ± Std. Deviation95% Confidence Interval for Mean
Lower BoundUpper Bound
Albumin (g/dL)163.177 ± 0.88412.2494.104
21354.124 ± 0.65734.0124.236
31133.633 ± 0.72133.4983.768
4643.352 ± 0.72173.1713.534
552.625 ± 0.15002.3862.864
WBC (K/μL)1611 005.00 ± 2944.2407915.2114 094.79
213510 266.98 ± 4291.9349533.6111 000.34
311310 404.28 ± 3755.0479704.3711 104.19
46410 675.87 ± 3795.4289720.0111 631.74
5511 900.00 ± 4874.4234143.7119 656.29
Hb (g/dL)1612.687 ± 1.189711.43813.935
213512.476 ± 1.737212.17912.773
311311.894 ± 1.704611.57612.212
46417.506 ± 24.244711.40023.612
559.150 ± 1.50006.76311.537
Total32313.223 ± 11.011912.01214.434
HbA1c (%)167.050 ± 0.21686.8227.278
21356.890 ± 0.53316.7996.981
31137.246 ± 0.57587.1387.353
4647.864 ± 0.54387.7218.007
558.350 ± 0.10008.1918.509
CRP (mg/dL)163.5000 ± 1.007972.44224.5578
21353.8254 ± 3.165793.26724.3836
31134.5909 ± 3.320263.92875.2531
4646.5871 ± 5.019655.31237.8618
554.9250 ± 1.250002.93606.9140
Creatinine (mg/dL)161.3400 ± 0.565510.74651.9335
21351.2484 ± 0.606551.13681.3599
31131.9936 ± 1.603591.66692.3202
4642.4945 ± 1.634022.05692.9321
553.0000 ± 2.09523−2.20488.2048
The distribution of laboratory markers in regards of American Society of Anesthesiologists Classification (ASA) The 69 of the patients (21%) had re‐amputation. All laboratory parameters were found as statistically significant except Hb levels when compared re‐amputation required patients with stabile patients who does not required re‐amputation. The lower albumin levels and Higher WBC, HbA1C, CRP, and creatinine levels detected in re‐amputation group. Duration of diabetes was detected as 15.5 ± 11.6 years in re‐amputation group and 8.64 ± 8.1 years in stabile group (P < 0.001). Comparison of laboratory parameters in regards of re‐amputation was presented at Table 6.
TABLE 6

Comparison of the re‐amputation and stabile groups

Laboratory ParameterRe‐amputationMean ± Std. Deviation P
Albumin (g/dL)3.896 ± 0.73390.001
+3.230 ± 0.6939
WBC (K/μL)10 024.13 ± 3942.6560.001
+11 882.46 ± 3725.957
Hb (g/dL)12.599 ± 6.81350.250
+15.402 ± 19.7597
HbA1c (%)7.082 ± 0.60980.001
+7.760 ± 0.5766
CRP (mg/dL)4.2828 ± 3.535330.001
+6.1090 ± 4.24402
Creatinine (mg/dL)1.5702 ± 1.126740.001
+2.5660 ± 1.80507
Comparison of the re‐amputation and stabile groups HbA1c, creatinine, and CRP levels were found as upper to reference line in ROC curve analyse (Figure 1). The cut‐off values were determined for predictor potential of these parameters for re‐amputation. The optimal cut‐off value of serum HbA1C levels was found as >7.05 for predicting re‐amputation with 86.7% sensitivity and 59.0% specificity (AUC: 0.785, 95% CI: 0.728–0.842). The optimal cut‐off value of serum CRP levels was found as >4.05 mg/dL for predicting re‐amputation with 61.2% sensitivity and 63.5% specificity (AUC: 0.627, 95% CI: 0.550–0.704). The optimal cut‐off value of serum creatinine levels was found as >1.60 mg/dL for predicting re‐amputation with 56.6% sensitivity and 69.0% specificity (AUC: 0.690, 95% CI: 0.609–0.770).
FIGURE 1

The ROC curve analyses of blood parameters for prediction re‐amputation in diabetic foot

The ROC curve analyses of blood parameters for prediction re‐amputation in diabetic foot

DISCUSSION

Our results indicate that there can be a strong relationship between higher HbA1C, (C‐reactive protein) CRP and creatinine levels, and higher‐level amputations in diabetic foot patients. Moreover, it seems to be that wound depth strongly associated that lower albumin, and higher HbA1C, CRP levels. Another quite remarkable finding of our study is related about prediction re‐amputation rates with increased value of serum HbA1C (with a cut‐off value of), CRP (with a cut‐off value of 4.05), and creatinine (with a cut‐off value of 1.6) levels. Especially, in according to our results HbA1C is the most sensitive predictor for re‐amputation in diabetic foot (optimal cut‐off value: 7.05 with 86% sensitivity and 59% specificity). Previous studies also focused to investigate blood parameters for determining to prognosis of diabetes and also diabetic foot. Icer et al found that albumin, haemoglobin, WBC, neutrophils, neutrophil/lymphocyte ratio, HbA1c levels were related extremity amputation. Also, they claimed that disease duration is related amputation because of impaired glucose metabolism. In previous studies, lower albumin levels were associated with poor prognosis for many kind of circulatory problems. , In in vitro models reduced albumin levels were related with increased plasma protein glycation and also negatively correlated with increased HbA1c levels. In another study lower albumin levels were associated with poorly controlled diabetes and also elevated HbA1c levels. Also, low serum albumin levels were suggested as a risk factor for nonhealing diabetic foot ulcers and poor prognosis. The other study about length of hospital stay in diabetic foot found that WBC count, CRP levels, and albumin levels were strongly correlated with long term hospital stay. Furthermore, poor prognosis predictors decremental albumin levels and incremental HbA1c are strongly related with elevated plasma protein glycation that irreversibly impairs the wound healing physiology from cells‐to‐organs. Also wound healing mechanisms; as migration, proliferation, and transdifferentiation steps are affected due to the toxic effects of impaired blood glucose control. Also, CRP as predictor for active inflammation was shown as a risk factor for amputation in diabetic foot ulcers. Similarly, Volaco et al, suggested that higher CRP levels are strong predictor for major amputation for patients with ischemic diabetic foot lesions. In another study increased levels of WBC and CRP was associated with poor prognosis and therapeutic failure of diabetic foot ulcers. Additionally, in another study it was claimed that lower serum albumin levels show also poor prognosis and associated with increased amputation risk. Likewise, HbA1c well‐known marker of detecting glycaemic control for last 2 to 3 months, have gained importance and have been comprehensively investigated in relation with diabetic foot ulcers, gangrene, and limb amputation. There are several conflicting reports about amputation risk and HbA1c levels in literature. Nerone et al, detected that major amputations was not affected to elevated HbA1c levels. Similarly, O'Connor et al found that there was not significant relation between HbA1c levels and risk of peripheral artery disease (PAD) and re‐intervention requirement in patients with critical limb ischemia. Oppositely, it was shown that HbA1c levels was an independent risk factor for determining to the amputation level as below knee or above knee in Nather et al's research. Similarly, we found that elevated HbA1C closely related with higher level of extremity amputation and independent predictor for re‐amputation in patients with diabetic foot. As supporting data of our findings, there was an evidence based results that determines 1% increase in HbA1c levels is associated 26% increases in the prevalence of PAD which can be directly related with higher risk of major limb loss. Almost the similar with literature we found significantly lower albumin levels, and markedly higher WBC, HbA1c, CRP, and creatinine levels, and longer disease durations in re‐amputation patients with diabetic foot ulcers. Even, we found that HbA1C, CRP, and creatinine are sensible laboratory markers for amputation. In conclusion the main point for amputation and/or re‐amputation for diabetic foot ulcers seems to be related with impaired glucose metabolism. The reflective blood parameters about this point such as albumin, WBC, CRP, and HbA1c can be useful for determining to the amputation risk. Especially, we suggest that higher HbA1c levels is highly sensitive for predicting to the amputation risk, in according to our results.

CONFLİCT OF INTEREST

The authors declare no conflicts of interest.
  21 in total

1.  Simple blood tests as predictive markers of disease severity and clinical condition in patients with venous insufficiency.

Authors:  Oguz Karahan; Celal Yavuz; Nazim Kankilic; Sinan Demirtas; Orhan Tezcan; Ahmet Caliskan; Binali Mavitas
Journal:  Blood Coagul Fibrinolysis       Date:  2016-09       Impact factor: 1.276

2.  Plasma albumin concentration is a predictor of HbA1c among type 2 diabetic patients, independently of fasting plasma glucose and fructosamine.

Authors:  Santiago Rodríguez-Segade; Javier Rodríguez; Dolores Mayan; Felix Camiña
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

Review 3.  Wound healing and its impairment in the diabetic foot.

Authors:  Vincent Falanga
Journal:  Lancet       Date:  2005-11-12       Impact factor: 79.321

4.  Hemoglobin A1c as a measure of disease severity and outcome in limb threatening ischemia.

Authors:  David J O'Connor; Nicholas J Gargiulo; Jennifer Jang
Journal:  J Surg Res       Date:  2011-07-23       Impact factor: 2.192

5.  Reamputation after minor foot amputation in diabetic patients: risk factors leading to limb loss.

Authors:  Vincent S Nerone; Kevin D Springer; Darren M Woodruff; Said A Atway
Journal:  J Foot Ankle Surg       Date:  2013 Mar-Apr       Impact factor: 1.286

6.  Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.

Authors:  Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

7.  Outcome of critical foot ischaemia in longstanding diabetic patients: a retrospective cohort study in a specialised tertiary care centre.

Authors:  A Volaco; E Chantelau; B Richter; B Luther
Journal:  Vasa       Date:  2004-02       Impact factor: 1.961

8.  Factors Associated with a Prolonged Length of Hospital Stay in Patients with Diabetic Foot: A Single-Center Retrospective Study.

Authors:  Sang Kyu Choi; Cheol Keun Kim; Dong In Jo; Myung Chul Lee; Jee Nam Kim; Hyun Gon Choi; Dong Hyeok Shin; Soon Heum Kim
Journal:  Arch Plast Surg       Date:  2017-11-10

Review 9.  Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing.

Authors:  Jorge Berlanga-Acosta; Gregory S Schultz; Ernesto López-Mola; Gerardo Guillen-Nieto; Marianela García-Siverio; Luis Herrera-Martínez
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

10.  Analysis of routine blood markers for predicting amputation/re-amputation risk in diabetic foot.

Authors:  Anıl Gülcü; Mustafa Etli; Oğuz Karahan; Ahmet Aslan
Journal:  Int Wound J       Date:  2020-10-05       Impact factor: 3.315

View more
  2 in total

Review 1.  Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease.

Authors:  Pavel Poredoš; Mišo Šabovič; Mojca Božič Mijovski; Jovana Nikolajević; Pier Luigi Antignani; Kosmas I Paraskevas; Dimitri P Mikhailidis; Aleš Blinc
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

2.  Analysis of routine blood markers for predicting amputation/re-amputation risk in diabetic foot.

Authors:  Anıl Gülcü; Mustafa Etli; Oğuz Karahan; Ahmet Aslan
Journal:  Int Wound J       Date:  2020-10-05       Impact factor: 3.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.